Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

Evans, D. G., Howell, S. J., & Howell, A. (2019). Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy? Familial Cancer, 18(4), 377–379. https://doi.org/10.1007/s10689-019-00142-8